Heparan Sulphate Binding BMP2 for Bone Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The interaction between glycosaminoglycans (GAGs) and growth factors, such as BMP2, is not fully understood, limiting the modulation and utilization of these interactions for therapeutic purposes, particularly in tissue repair and regeneration.
Innovation Solution
A heparan sulphate preparation, HS/BMP2, is developed, which is capable of binding to BMP2 with high affinity, enhancing its bioactivity and is used in compositions for tissue repair, regeneration, and bone formation, either alone or in combination with BMP2 protein and mesenchymal stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If heparin affinity chromatography is used to purify growth factors, then purification is achieved, but the specific binding interactions between GAGs and growth factors remain unclear
Solution Approach 1:
The patent extracts and isolates specific glycosaminoglycan sequences that bind to BMP2 from complex heparin preparations. By separating the binding-active GAG sequences from non-binding components, the invention identifies the specific molecular interactions while maintaining the purification function, thus resolving the contradiction between purification and understanding interactions.
Solution Approach 2:
The patent uses heparin affinity chromatography as an intermediary step to enrich GAGs that bind to BMP2, then applies further purification steps to isolate specific binding sequences. This multi-stage approach allows the intermediary chromatography method to capture binding interactions while subsequent steps clarify the specific molecular mechanisms.
2Adaptability or versatility
If the interaction between GAGs and BMP2 is not fully understood, then broad applicability is maintained, but therapeutic modulation and utilization are limited
Solution Approach 1:
The patent identifies specific local sequences within GAG molecules that are responsible for BMP2 binding. By characterizing these local binding domains rather than treating all GAGs as uniform, the invention enables targeted therapeutic applications with predictable efficacy while maintaining the ability to select different GAG variants for different applications.
3Ease of manufacture
If non-specific GAG-protein interactions are used, then ease of manufacture is improved, but binding affinity and bioactivity enhancement are reduced
Solution Approach 1:
The patent changes the parameters of GAG selection from generic heparin to specific heparan sulfate sequences with characterized BMP2-binding activity. By adjusting the molecular characteristics (sulfation patterns, sequence composition) of the GAG component, the invention achieves both manufacturability through established chromatography methods and high binding affinity through sequence-specific selection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
HS/BMP2 effectively promotes the generation, repair, and regeneration of connective tissue, including bone, by enhancing BMP2-induced activities and prolonging its signaling effects, thereby facilitating faster and more effective tissue healing and regeneration.
Implementation Method 1
HS/BMP2 is capable of binding a peptide or polypeptide having, or consisting of, the amino acid sequence of SEQ ID NO:1 or 6... HS/BMP2 binds to a peptide having or consisting of the amino acid sequence of SEQ ID NO:1 or 6 with a KD of less than 100 μM
Data Source
AI summary
Heparan sulphate HS/BMP2 is disclosed, together with the use of HS/BMP2 in the repair and regeneration of bone tissue.